Sympathetic activation in cardiovascular and renal disease

Journal of Nephrology

Volumn 22, Issue 2, 2009, Pages 190-195

  Grassi, Guido ^a,b,c   Arenare, Francesca ^a   Pieruzzi, Federico ^a   Brambilla, Gianmaria ^a   Mancia, Giuseppe ^a,b,c  

^a SAN GERARDO HOSPITAL   (Italy)

^b Center of Clinical Physiology and Hypertension   (Italy)

^c Auxologico Center   (Italy)

Author keywords

Hypertension; Renal failure; Sympathetic activity; Sympathoinhibitory drugs

Indexed keywords

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ADRENERGIC TRANSMISSION; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; ESSENTIAL HYPERTENSION; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; METABOLIC SYNDROME X; OBESITY; ORGAN INJURY; REVIEW; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADRENERGIC RECEPTOR BLOCKING AGENT;

CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS;

EID: 67649407881     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Grassi G, Cattaneo BM, Mancia G. Sympathetic nervous system. In: Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJ, eds. Heart failure: scientific principles and clinical practice. New York: Churchill Livingstone; 1997:199-214.
2. Grassi G. Qualitative assessment of sympathetic neural drive in cardiometabolic disease: a new challenge. Hypertension. 2007;50:835-836.
3. Mancia G, Bousquet P, Elghozi JL, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007;25:909-920.
4. Jordan J, Grassi G. Adrenergic overdrive: a "not-so-sympathetic" risk factor in renal failure patients. J Hypertens. 2007;25:1197-1199.
5. Campese VM, Park J. The kidney and hypertension: over 70 years of research. J Nephrol. 2006;19:691-698.
6. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1999;17:719-734.
7. Julius S, Krause L, Schork NJ, et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens. 1991;9:77-84.
8. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension. 1989;14:177-183.
9. Esler M, Lambert G, Jennings G. Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens. 1989;11:75-89.
10. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31:68-72.
11. Grassi G, Mancia G. Neurogenic hypertension: is the enigma of its origin near the solution? Hypertension. 2004;43:154-155.
12. Esler M, Ferrier C, Lambert G, et al. Biochemical evidence of sympathetic hyperactivity in human hypertension. Hypertension. 1991;17:29-35.
13. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560-565.
14. Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DA, Greenwood JP. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007;115:1999-2005.
15. Grassi G, Seravalle G, Quarti-Trevano F, et al. Neurogenic abnormalities in masked hypertension. Hypertension. 2007;50:537-542.
16. Grassi G, Seravalle G, Quarti-Trevano F, et al. Adrenergic, metabolic and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension. 2008;52:925-931.
17. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 1978;41:233-243.
18. Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE, Sundlöf G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation. 1986;73:913-919.
19. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 1995;92:3206-3211.
20. Grassi G, Seravalle G, Bertinieri G, et al. Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. Clin Sci (Lond). 2001;101:141-146.
21. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
22. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J. 2001;22:1136-1143.
23. Grassi G. Sympathetic deactivation as a goal of nonpharmacologic and pharmacologic antihypertensive treatment: rationale and options. Curr Hypertens Rep. 2003;5:277-280.
24. Grassi G. Adrenergic overdrive as the link among hypertension, obesity, and impaired thermogenesis: lights and shadows. Hypertension. 2007;49:5-6.
25. Bigazzi R, Bianchi S. Insulin resistance, metabolic syndrome and endothelial dysfunction. J Nephrol. 2007;20:10-14.
26. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25:560-563.
27. Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens. 2004;22:2363-2369.
28. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation. 1997;96:3423-3429.
29. Huggett RJ, Burns J, Mackintosh AF, Mary DA. Sympathetic neural activation in non diabetic metabolic syndrome and its further augmentation by hypertension. Hypertension. 2004;44:847-852.
30. Grassi G, Dell'Oro R, Quarti-Trevano F, et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005;48:1359-1365.
31. Schultz HD, Li YL, Ding Y. Arterial chemoreceptors and sympathetic nerve activity: implications for hypertension and heart failure. Hypertension. 2007;50:6-13.
32. Grassi G, Facchini A, Quarti-Trevano F, et al. Obstructive sleep apnea-dependent and independent adrenergic activation in obesity. Hypertension. 2005;46:321-325.
33. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87:2246-2252.
34. Grassi G. Leptin, sympathetic nervous system, and baroreflex function. Curr Hypertens Rep. 2004;6:236-240.
35. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354-1359.
36. Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912-1918.
37. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974-1979.
38. Grassi G, Quarti Trevano F, Arenare F, et al. Early sympathetic activation in mild renal failure. J Hypertens. 2006;24:342.
39. Hering D, Zdrojewski Z, Krol E, et al. Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure. J Hypertens. 2007;25:157-161.
40. Hausberg M, Grassi G. Mechanisms of sympathetic overactivity in patients with chronic renal failure: a role for chemoreflex activation? J Hypertens. 2007;25:47-49.
41. Mancia G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Grassi G. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens. 2006;24:51-56.
42. Mallamaci F, Tripepi G, Maas R, Malatino L, Boger R, Zoccali C. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol. 2004;15:435-441.
43. Perticone F, Maio R, Tripepi G, Sciacqua A, Mallamaci F, Zoccali C. Microalbuminuria, endothelial dysfunction and inflammation in primary hypertension. J Nephrol. 2007;20:S56-S62.
44. Zoccali C. The endothelium as a target in renal diseases. J Nephrol. 2007;20:S39-S44.
45. Quarti Trevano F, Ilardo V, Seravalle G, et al. Adrenergic overdrive and relationship with metabolic and cardiac abnormalities in chronic renal failure. J Hypertens. 2007;25:16.
46. Schlaich MP, Socratous F, Hennebry S, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2008 Sep 17.
47. Grassi G, Seravalle G, Arenare F, et al. Non-uniform regional distribution of the adrenergic overdrive in chronic renal failure. J Hypertens. 2009 (in press).
48. Zoccali C, Mallamaci F, Tripepi G, et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension. 2002;40:41-46.
49. Zilch O, Vos PF, Oey PL, et al. Sympathetic hyperactivity in haemodialysis patients is reduced by short-daily haemodialysis. J Hypertens. 2007;25:1285-1289.
50. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340:1321-1328.
51. Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol. 2004;15:2902-2907.